Clinical Trials Logo

Clinical Trial Summary

the purpose of this study is to evaluate the efficacy and safety of pivmecillinam hydrochloride tablets in the treatment of uncomplicated urinary tract infection in China


Clinical Trial Description

Screening period (D -3 to D -1): complete screening examinations will be performed after the subject signs the informed consent Dosing Treatment Period (D 1 to D 5): subjects who met the inclusion criteria and did not meet the exclusion criteria were randomized. Refer to the randomization protocol for specific randomization process. Safety check (D 5+1): perform on-site visit after 15 doses (D 5+1) Post-treatment follow-up assessments ((D 12±2) and (D 21+7)): subjects returned to the study site for on-site follow-up on Day 12±2 and Day 21+7. Urine bacterial culture and minimal inhibitory concentration (MIC) test: urine bacterial culture is required for subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05545137
Study type Interventional
Source Greenpine Pharma Group Co., ltd.
Contact
Status Completed
Phase Phase 3
Start date September 29, 2022
Completion date February 20, 2024

See also
  Status Clinical Trial Phase
Completed NCT01913860 - Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle) N/A
Completed NCT03716804 - Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community Phase 4
Completed NCT03425396 - Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis Phase 2